JP2022523368A - １－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態 - Google Patents

１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態 Download PDF

Info

Publication number
JP2022523368A
JP2022523368A JP2021549407A JP2021549407A JP2022523368A JP 2022523368 A JP2022523368 A JP 2022523368A JP 2021549407 A JP2021549407 A JP 2021549407A JP 2021549407 A JP2021549407 A JP 2021549407A JP 2022523368 A JP2022523368 A JP 2022523368A
Authority
JP
Japan
Prior art keywords
compound
weight
cancer
disease
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523368A5 (https=
Inventor
レイス，カリナ
キンペ，クリストフ，レオナルド
ガートマン，ロバート，マイケル
ウェイ，ハオジュアン
ジョウ，ペン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022523368A publication Critical patent/JP2022523368A/ja
Publication of JP2022523368A5 publication Critical patent/JP2022523368A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021549407A 2019-02-22 2020-02-20 １－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態 Pending JP2022523368A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/075834 2019-02-22
CN2019075834 2019-02-22
PCT/EP2020/054485 WO2020169736A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Publications (2)

Publication Number Publication Date
JP2022523368A true JP2022523368A (ja) 2022-04-22
JP2022523368A5 JP2022523368A5 (https=) 2023-02-28

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549407A Pending JP2022523368A (ja) 2019-02-22 2020-02-20 １－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態

Country Status (21)

Country Link
US (1) US12269813B2 (https=)
EP (1) EP3927696B1 (https=)
JP (1) JP2022523368A (https=)
KR (1) KR20210131371A (https=)
CN (1) CN113474339B (https=)
AU (1) AU2020226723B2 (https=)
BR (1) BR112021016400A2 (https=)
CA (1) CA3129623A1 (https=)
EA (1) EA202192320A1 (https=)
EC (1) ECSP21067828A (https=)
ES (1) ES2966132T3 (https=)
IL (1) IL285675A (https=)
JO (1) JOP20210227A1 (https=)
MA (1) MA55019A (https=)
MX (1) MX2021010133A (https=)
PE (1) PE20212067A1 (https=)
PH (1) PH12021552018A1 (https=)
SG (1) SG11202108909SA (https=)
TW (1) TW202045495A (https=)
UY (1) UY38592A (https=)
WO (1) WO2020169736A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
TW202227067A (zh) 2020-08-21 2022-07-16 比利時商健生藥品公司 Ｍａｌｔ１抑制劑之無定形形式及其配製物
BR112023017648A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
MX2024001840A (es) 2021-08-09 2024-02-28 Janssen Pharmaceutica Nv Composiciones para usar en el tratamiento de neoplasias de celulas b.
WO2025073968A1 (en) 2023-10-06 2025-04-10 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180170909A1 (en) * 2016-12-21 2018-06-21 Janssen Biotech, Inc. Pyrazole derivatives as malt1 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098515A2 (en) 2003-04-30 2004-11-18 Agensys, Inc. Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
JP2009533327A (ja) * 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
ES2539379T3 (es) 2010-06-22 2015-06-30 Basf Se Procedimiento de preparación de 4-hidroxipiridinas
JP6231085B2 (ja) * 2012-05-31 2017-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アミノキナゾリン誘導体及びピリドピリミジン誘導体
SG11201607895PA (en) 2014-05-28 2016-12-29 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
AU2015300966A1 (en) 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
WO2016209688A1 (en) * 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
AU2016352813B2 (en) 2015-11-13 2019-09-19 Novartis Ag Novel pyrazolo pyrimidine derivatives
US10882841B2 (en) 2016-03-01 2021-01-05 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
US20200009135A1 (en) 2017-02-01 2020-01-09 Medivir Ab Therapeutic applications of malt1 inhibitors
AU2018395291A1 (en) 2017-12-28 2020-07-30 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
EP3756268A1 (de) 2018-02-23 2020-12-30 Industrieanlagen-Betriebsgesellschaft mbH Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
TW202227067A (zh) * 2020-08-21 2022-07-16 比利時商健生藥品公司 Ｍａｌｔ１抑制劑之無定形形式及其配製物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180170909A1 (en) * 2016-12-21 2018-06-21 Janssen Biotech, Inc. Pyrazole derivatives as malt1 inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"医薬品の塩選択，結晶多形のスクリーニングの重要性について", 薬剤学, vol. 第66巻、第6号, JPN6024037935, 2006, pages 435 - 439, ISSN: 0005426144 *
"医薬品開発における結晶形選択の効率化を目指して", 薬剤学, vol. 68巻5号, JPN6024037937, 2008, pages 344 - 349, ISSN: 0005426146 *
"製剤化のための最適な原薬の結晶形態の設計", 化学工学会 研究発表講演要旨集, JPN6024037936, 2010, pages 436 - 437, ISSN: 0005426145 *
JOURNAL OF MEDICINE, vol. 19, no. 2, JPN6008003682, 1988, US, pages 109 - 117, ISSN: 0005248891 *
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 2009, Vol.13, No.6, JPN6020035450, pages 1241 - 1253, ISSN: 0005426140 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005426141 *
社団法人日本化学会編, 第４版実験化学講座１基本操作Ｉ, vol. 第１８４−１８９頁, JPN7008003682, 5 April 1996 (1996-04-05), ISSN: 0005426142 *
第十六改正 日本薬局方, JPN6014035187, 2011, pages 64 - 68, ISSN: 0005285936 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005426143 *

Also Published As

Publication number Publication date
UY38592A (es) 2020-08-31
WO2020169736A1 (en) 2020-08-27
IL285675A (en) 2021-10-31
TW202045495A (zh) 2020-12-16
EP3927696B1 (en) 2023-10-18
PH12021552018A1 (en) 2022-09-19
KR20210131371A (ko) 2021-11-02
ES2966132T3 (es) 2024-04-18
CN113474339B (zh) 2025-02-25
ECSP21067828A (es) 2021-11-18
EA202192320A1 (ru) 2021-11-16
AU2020226723A1 (en) 2021-08-19
CN113474339A (zh) 2021-10-01
EP3927696A1 (en) 2021-12-29
EP3927696C0 (en) 2023-10-18
SG11202108909SA (en) 2021-09-29
US20220127249A1 (en) 2022-04-28
US12269813B2 (en) 2025-04-08
MX2021010133A (es) 2021-09-23
CA3129623A1 (en) 2020-08-27
BR112021016400A2 (pt) 2021-10-13
AU2020226723B2 (en) 2025-01-23
MA55019A (fr) 2021-12-29
JOP20210227A1 (ar) 2021-08-18
PE20212067A1 (es) 2021-10-26

Similar Documents

Publication Publication Date Title
JP2022523368A (ja) １－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－［２－（トリフルオロメチル）ピリジン－４－イル］－１ｈ－ピラゾール－４－カルボキサミド一水和物の結晶形態
AU2019392683B2 (en) Combination therapies
WO2020055755A1 (en) Combination therapies
KR20250005505A (ko) 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
WO2023059598A1 (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
KR20200144579A (ko) 피리미딘 유도체의 약학 염 및 장애의 치료 방법
WO2012073184A1 (en) Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases
WO2021017384A1 (zh) 二氢吡咯并嘧啶类选择性jak2抑制剂
TWI796250B (zh) 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
KR20140040671A (ko) 아프레피탄트 l-프롤린 조성물 및 공결정
CN118439992A (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
CN111662275A (zh) 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
EA045924B1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-(2-(трифторметил)пиридин-4-ил)-1h-пиразол-4-карбоксамида
HK40052643A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
JP2021527120A (ja) 塩形態
JP2021527119A (ja) 塩形態
TW201829398A (zh) 酪胺酸蛋白激酶調節劑、晶型及其用途
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
WO2026068848A1 (en) N-substituted 9-aminoacridines and their use in the treatment of cancer
WO2026068857A1 (en) N-substituted 9-aminoacridines and their use in the treatment of cancer
HK40072166B (zh) 杂环化合物及其制备方法和用途
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001